Free Trial
NYSEAMERICAN:LCTX

Lineage Cell Therapeutics (LCTX) Stock Price, News & Analysis

Lineage Cell Therapeutics logo
$0.98 +0.03 (+3.63%)
Closing price 04:10 PM Eastern
Extended Trading
$1.00 +0.02 (+1.53%)
As of 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Lineage Cell Therapeutics Stock (NYSEAMERICAN:LCTX)

Key Stats

Today's Range
$0.94
$1.03
50-Day Range
$0.44
$1.08
52-Week Range
$0.37
$1.15
Volume
956,050 shs
Average Volume
1.59 million shs
Market Capitalization
$224.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.20
Consensus Rating
Buy

Company Overview

Lineage Cell Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
56th Percentile Overall Score

LCTX MarketRank™: 

Lineage Cell Therapeutics scored higher than 56% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lineage Cell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Lineage Cell Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Lineage Cell Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Lineage Cell Therapeutics are expected to grow in the coming year, from ($0.12) to ($0.09) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lineage Cell Therapeutics is -12.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lineage Cell Therapeutics is -12.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lineage Cell Therapeutics has a P/B Ratio of 2.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Lineage Cell Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    17.19% of the float of Lineage Cell Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lineage Cell Therapeutics has a short interest ratio ("days to cover") of 17.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Lineage Cell Therapeutics has recently decreased by 2.31%, indicating that investor sentiment is improving.
  • Dividend Yield

    Lineage Cell Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Lineage Cell Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    17.19% of the float of Lineage Cell Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lineage Cell Therapeutics has a short interest ratio ("days to cover") of 17.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Lineage Cell Therapeutics has recently decreased by 2.31%, indicating that investor sentiment is improving.
  • News Sentiment

    Lineage Cell Therapeutics has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Lineage Cell Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    Only 3 people have searched for LCTX on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lineage Cell Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    26.80% of the stock of Lineage Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    62.47% of the stock of Lineage Cell Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lineage Cell Therapeutics' insider trading history.
Receive LCTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LCTX Stock News Headlines

LCTX Lineage Cell Therapeutics, Inc. - Seeking Alpha
Trump’s biggest move, misreported
The media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada the 51st state because he’s desperate for critical minerals… They think his involvement in Ukraine is just another resource grab… They think his tariffs will wreck the economy… But they’re all missing the bigger picture.
Lineage Cell Therapeutics appoints new auditor
See More Headlines

LCTX Stock Analysis - Frequently Asked Questions

Lineage Cell Therapeutics' stock was trading at $0.5150 at the beginning of the year. Since then, LCTX shares have increased by 93.2% and is now trading at $0.9950.

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) released its quarterly earnings results on Thursday, August, 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.01. The firm had revenue of $1.41 million for the quarter, compared to analysts' expectations of $1.28 million. Lineage Cell Therapeutics had a negative trailing twelve-month return on equity of 22.64% and a negative net margin of 169.57%.
Read the conference call transcript
.

Shares of LCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lineage Cell Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Moderna (MRNA), JPMorgan Chase & Co. (JPM) and Chevron (CVX).

Company Calendar

Last Earnings
8/08/2024
Today
7/08/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSEAMERICAN:LCTX
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.20
High Stock Price Target
$9.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+341.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$18.61 million
Net Margins
-169.57%
Pretax Margin
-169.16%

Debt

Sales & Book Value

Annual Sales
$9.50 million
Price / Cash Flow
N/A
Book Value
$0.35 per share
Price / Book
2.72

Miscellaneous

Free Float
167,157,000
Market Cap
$217.03 million
Optionable
Not Optionable
Beta
1.60
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NYSEAMERICAN:LCTX) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners